Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 in metastatic breast cancer
NCT00511459Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2007
- Primary completion
- Aug 2010
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of trebananib in breast cancer (4 arms), sponsored by Amgen. Primary endpoint: Progression-Free Survival at 3 years. Started Jul 2007; status: completed.
02
Drugs
trebananib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00511459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511459.